In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

Don't Miss a Beat hosts are joined by Alexandre Mebazaa, MD, PhD, lead investigator of the STRONG-HF trial, to discuss the inspiration for the trial, its design, and important takeaways for those looking to implement a similar strategy of rapid, in-hospital uptitration of GDMT in heart failure at their own practice.

Video Version

Muthiah Vaduganathan, MD, MPH, of Brigham and Women’s Hospital, and Stephen Greene, MD, of the Duke University School of Medicine, are bringing you insights from the floor at the American Heart Association 2022 Scientific Sessions in Chicago, Il. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

In this episode of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, provide a recap of the European Society of Cardiology Congress 2022. This recap begins with a discussion on the results of the phase 3 DELIVER trial, in which Vaduganathan served as an investigator, the ADVOR trial, and REVIVED. 

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of eGFR slope as an end point in clinical trials and as a tool in clinical practice. 

A first-in-class allosteric and reversible inhibitor selective for cardiac myosin approved based on the results of the EXPLORER-HCM trial, mavacamten was approved for the treatment of adults with symptomatic NYHA class 2-3 obstructive hypertrophic cardiomyopathy after their phase 3 data indicated use was with improved exercise capacity, LVOT obstruction, NYHA functional class, and health status patients with oHCM. 
In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD, of Penn Medicine. An assistant professor of medicine in the Division of Cardiology and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens is a leading researcher in oHCM with real-world clinical experience treating the disease. During the episode, Owens takes our hosts on a deep dive into the disease state from her perspective. 

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

Headed to ACC.22 this weekend or following along virtually? Get the weekend started with our special ACC.22 preview edition of Don't Miss a Beat. Hear from co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting and offer their thoughts on the recent EMPA-KIDNEY announcement.